Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults > 65: Results From a Phase 3b, Open-Label Trial

As the age of people living with HIV increases, studies are needed to assess the safety and efficacy of antiretroviral therapy. Older individuals are at increased risk of comorbidities and polypharmacy, so ensuring the safety and tolerability of ART is critical. This poster shows a study of B/F/TAF, a small, tolerable, single-tablet regimen with few drug-drug interactions, a high barrier to resistance, and no food restrictions that is effective in an aging population.